

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

on 2/7/02
Date of Deposit

Carolyn Roberts

Name of applicant, assignee
or Registered Representative

Carolyn Roberts
Signature

2/7/02
Date of Signature

PATENT
Case No. P-162-DIV-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Pamukcu, et al.)	
)	
Serial No.:)	Group Art Unit: 1614
)	
Filed:)	Examiner: J. Goldberg
)	
For: METHOD OF INHIBITING NEOPLASTIC)	
CELLS WITH INDOLE DERIVATIVES)	

PRELIMINARY AMENDMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

Dear Sir:


Please enter the following amendments before calculating the filing fees in this case.

In the Specification:

On page 2, before "Background of the Invention": insert -- This application is a Divisional of prior U.S. Application Serial No. 09/199,860 entitled "Method for Inhibiting Neoplastic Cells with Indole Derivatives," which is incorporated herein by reference. --

CLEAN VERSIONS OF CLAIMS 1 AND 2 AS AMENDED

1. (amended) A method for inhibiting the growth of neoplastic cells sensitive to the compounds of formula I comprising exposing the cells to a growth inhibiting effective amount of a compound of Formula I:




(I)

wherein R₁ to R₃ each represent a lower alkyl group, an oxy group, an oxy-lower alkyl group, a lower alkyloxy group, a carbonyl group, a lower alkenyl group, an optionally-substituted imino group, a lower alkylimino group optionally substituted at its nitrogen atom, a thio-lower alkyl group, or a lower alkylthio group; to each group, bonded is an aryl group or a heterocyclic group, or each group is substituted by an aryl group or a heterocyclic group; and said aryl or heterocyclic group may be further substituted by any of a halogen atom, a nitro group, a lower alkylamino group, an acylamino group, a lower alkyl group, a lower alkoxy group, a halo-lower alkyl group, a lower cycloalkyl group, or an aryl, heterocyclic, aryl-lower alkyl, heterocyclic-lower alkyl, aryl-lower alkyloxy, heterocyclic-lower alkyloxy, aryl-lower alkenyl or heterocyclic-lower alkenyl group optionally substituted by any of a halogen atom or a lower alkyl group, with the proviso that R₁ to R₃ are not simultaneously hydrogen atoms;

R₄ is selected from the group consisting of hydrogen atom or lower alkyl;

R₅ is selected from the group consisting of carboxyl, an esterified carboxyl group, or an amidated carboxyl group.

2 (amended). A method of treating a mammal having precancerous lesions sensitive to the compounds of formula I comprising administering to said mammal a pharmacologically effective amount of a compound of Formula I:




wherein R₁ to R₃ each represent a lower alkyl group, an oxy group, an oxy-lower alkyl group, a lower alkyloxy group, a carbonyl group, a lower alkenyl group, an optionally-substituted imino group, a lower alkylimino group optionally substituted at its nitrogen atom, a thio-lower alkyl group, or a lower alkylthio group; to each group, bonded is an aryl group or a heterocyclic group, or each group is substituted by an aryl group or a heterocyclic group; and said aryl or heterocyclic group may be further substituted by any of a halogen atom, a nitro group, a lower alkylamino group, an acylamino group, a lower alkyl group, a lower alkoxy group, a halo-lower alkyl group, a lower cycloalkyl group, or an aryl, heterocyclic, aryl-lower alkyl, heterocyclic-lower alkyl, aryl-lower alkyloxy, heterocyclic-lower alkyloxy, aryl-lower alkenyl or heterocyclic-lower alkenyl group optionally substituted by any of a halogen atom or a lower alkyl group, with the proviso that R₁ to R₃ are not simultaneously hydrogen atoms;

R₄ is selected from the group consisting of hydrogen atom or lower alkyl;

R₅ is selected from the group consisting of carboxyl, an esterified carboxyl group, or an amidated carboxyl group.

VERSIONS WITH MARKINGS TO SHOW CHANGES OF CLAIMS 1 AND 2 AS
AMENDED

1. (amended) A method for inhibiting the growth of neoplastic cells sensitive to the compounds of formula I comprising exposing the cells to a growth inhibiting effective amount of a compound of Formula I:



(I)

wherein R₁ to R₃ each represent[;

(1) a hydrogen atom, or


(2) a lower alkyl group, a lower alkylthio group, or a lower alkoxy-lower alkyl group,

(3)] a lower alkyl group, an oxy group, an oxy-lower alkyl group, a lower alkyloxy group, a carbonyl group, a lower alkenyl group, an optionally-substituted imino group, a lower alkylimino group optionally substituted at its nitrogen atom, a thio-lower alkyl group, or a lower alkylthio group; to each group [in 3)], bonded is an aryl group or a heterocyclic group, or each group [in 3)] is substituted by an aryl group or a heterocyclic group; and said aryl or heterocyclic group may be further substituted by any of a halogen atom, a nitro group, a lower alkylamino group, an acylamino group, a lower alkyl group, a lower alkoxy group, a halo-lower alkyl group, a lower cycloalkyl group, or an aryl, heterocyclic, aryl-lower alkyl, heterocyclic-lower alkyl, aryl-lower alkyloxy, heterocyclic-lower alkyloxy, aryl-lower alkenyl or heterocyclic-lower alkenyl group optionally substituted by any of a halogen atom or a lower alkyl group, with the proviso that R₁ to R₃ are not simultaneously hydrogen atoms;

R₄ is selected from the group consisting of hydrogen atom or lower alkyl;

R₅ is selected from the group consisting of carboxyl, an esterified carboxyl group, or an amidated carboxyl group.

2 (amended). A method of treating a mammal having precancerous lesions sensitive to the compounds of formula I comprising administering to said mammal a pharmacologically effective amount of a compound of Formula I:



wherein R₁ to R₃ each represent[;

(1) a hydrogen atom, or

(2) a lower alkyl group, a lower alkylthio group, or a lower alkoxy-lower alkyl group,

(3)] a lower alkyl group, an oxy group, an oxy-lower alkyl group, a lower alkyloxy group, a carbonyl group, a lower alkenyl group, an optionally-substituted imino group, a lower alkylimino group optionally substituted at its nitrogen atom, a thio-lower alkyl group, or a lower alkylthio group; to each group [in 3)], bonded is an aryl group or a heterocyclic group, or each group [in 3)] is substituted by an aryl group or a heterocyclic group; and said aryl or heterocyclic group may be further substituted by any of a halogen atom, a nitro group, a lower alkylamino group, an acylamino group, a lower alkyl group, a lower alkoxy group, a halo-lower alkyl group, a lower cycloalkyl group, or an aryl, heterocyclic, aryl-lower alkyl, heterocyclic-lower alkyl, aryl-lower alkyloxy, heterocyclic-lower alkyloxy, aryl-lower alkenyl or heterocyclic-lower alkenyl group optionally substituted by any of a halogen atom or a lower alkyl group, with the proviso that R₁ to R₃ are not simultaneously hydrogen atoms;

R₄ is selected from the group consisting of hydrogen atom or lower alkyl;

R₅ is selected from the group consisting of carboxyl, an esterified carboxyl group, or an amidated carboxyl group.

REMARKS

This case is a divisional from U.S. Application Serial No. 09/199,860 where an Examiner's Amendment was made to claims 1 and 2 canceling portions of the claim. This case is filed to prosecute those portions of claims 1 and 2.

2-7-02
CELL PATHWAYS, INC.
702 Electronic Drive
Horsham, PA 19044
(215) 706-3800

Respectfully submitted,



Robert W. Stevenson - 31064
Attorney for Applicants